Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 66

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 66
---
 months

NOTE 14—NET (LOSS) INCOME PER COMMON SHARE

Potential common shares are excluded from the diluted net (loss) income per common share computation to the extent that they would be antidilutive. Since the Company reported a net loss for the year ended December 31, 2024, no potentially dilutive securities were included in the computation of diluted net loss per share for that period. As discussed in Note 10, Debt, the Company has the option to pay cash for the aggregate principal amount due upon the conversion of its 2025 Notes. For additional information on the Company’s computation of its net (loss) income per common share, see Note 2, Summary of Significant Accounting Policies.The following table sets forth the computation of basic and diluted net (loss) income per common share for the years ended December 31, 2024, 2023 and 2022 (in thousands, except per common share amounts):  Year Ended December 31, 202420232022Numerator:   Net (loss) income—basic$(99,560)$41,955 $15,909 2025 Notes if-converted method adjustment— 4,114 — Adjusted net (loss) income—diluted$(99,560)$46,069 $15,909 Denominator:Weighted average common shares outstanding—basic46,245 46,222 45,521 Computation of diluted securities:2025 Notes if-converted method adjustment— 5,608 — Dilutive effect of stock options— 51 787 Dilutive effect of RSUs— 96 226 Dilutive effect of ESPP share options— 2 4 Weighted average common shares outstanding—diluted46,245 51,979 46,538 Net (loss) income per common share:Basic net (loss) income per common share$(2.15)$0.91 $0.35 Diluted net (loss) income per common share$(2.15)$0.89 $0.34 The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net (loss) income per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):  Year Ended December 31, 202420232022Weighted average number of stock options